Small and Simple
SdAbs are 10x smaller and simpler than conventional antibodies, allowing better tissue penetration and target access, with reduced immunogenicity and faster clearance for safer therapies.
Our company
Welcome to Nanogrow!
We are developing cutting-edge biological treatments combining our unique Single-Domain Antibodies (SdAbs)-platform with the most convenient formulation.
Antibodies
Multi-Product Platform
Biotech
Pharmaceutical
Innovation
Ai
Targeted Therapies
Biological Therapies
Our Technology
Why SdAbs?
SAFE + SIMPLE + Successful
Unlock the future of targeted therapies with our innovative Single-domain Antibodies* technology. By leveraging deep immune system knowledge, our platform focuses on safer, simpler, and more successful solutions.
*Single-domain Antibodies (SdAbs) are the smallest antibody fragments with the specificity of an antibody. Their size allows for better tissue penetration and effectiveness in targeted therapies.
Stable structure
SdAbs’ simplicity ensures greater stability and resistance to degradation, enabling consistent performance across delivery systems and minimizing the risk of adverse reactions for safer therapies.
Building blocks
SdAbs’ versatility allows for easy modification, fusion with other molecules, and optimized binding, enhancing potency, specificity, and safety in therapeutic applications.
Easy manufacturing and high yield production
Due to their simplicity and stability, SdAbs can be produced in large quantities at low cost, enabling scalable, high-yield production across various expression systems.
Small and Simple
SdAbs are 10x smaller and simpler than conventional antibodies, allowing better tissue penetration and target access, with reduced immunogenicity and faster clearance for safer therapies.
Stable structure
SdAbs’ simplicity ensures greater stability and resistance to degradation, enabling consistent performance across delivery systems and minimizing the risk of adverse reactions for safer therapies.
Building blocks
SdAbs’ versatility allows for easy modification, fusion with other molecules, and optimized binding, enhancing potency, specificity, and safety in therapeutic applications.
Easy manufacturing and high yield production
Due to their simplicity and stability, SdAbs can be produced in large quantities at low cost, enabling scalable, high-yield production across various expression systems.
Small and Simple
SdAbs are 10x smaller and simpler than conventional antibodies, allowing better tissue penetration and target access, with reduced immunogenicity and faster clearance for safer therapies.
Stable structure
SdAbs’ simplicity ensures greater stability and resistance to degradation, enabling consistent performance across delivery systems and minimizing the risk of adverse reactions for safer therapies.
Building blocks
SdAbs’ versatility allows for easy modification, fusion with other molecules, and optimized binding, enhancing potency, specificity, and safety in therapeutic applications.
Easy manufacturing and high yield production
Due to their simplicity and stability, SdAbs can be produced in large quantities at low cost, enabling scalable, high-yield production across various expression systems.
Small and Simple
SdAbs are 10x smaller and simpler than conventional antibodies, allowing better tissue penetration and target access, with reduced immunogenicity and faster clearance for safer therapies.
Stable structure
SdAbs’ simplicity ensures greater stability and resistance to degradation, enabling consistent performance across delivery systems and minimizing the risk of adverse reactions for safer therapies.
Building blocks
SdAbs’ versatility allows for easy modification, fusion with other molecules, and optimized binding, enhancing potency, specificity, and safety in therapeutic applications.
Easy manufacturing and high yield production
Due to their simplicity and stability, SdAbs can be produced in large quantities at low cost, enabling scalable, high-yield production across various expression systems.
Small and Simple
SdAbs are 10x smaller and simpler than conventional antibodies, allowing better tissue penetration and target access, with reduced immunogenicity and faster clearance for safer therapies.
Stable structure
SdAbs’ simplicity ensures greater stability and resistance to degradation, enabling consistent performance across delivery systems and minimizing the risk of adverse reactions for safer therapies.
Building blocks
SdAbs’ versatility allows for easy modification, fusion with other molecules, and optimized binding, enhancing potency, specificity, and safety in therapeutic applications.
Easy manufacturing and high yield production
Due to their simplicity and stability, SdAbs can be produced in large quantities at low cost, enabling scalable, high-yield production across various expression systems.
Why We’re Different
Our Unique Edge
Our team's expertise with nanobodies enhances their applications, maximizing their value and synergizing with other technologies. Discover how our unique approach sets us apart.
Targeted-Tailored Strategy
Innovative Expertise: Single-Domain Antibody Discovery
Characterization of SdAbs
Advanced Delivery
Targeted-Tailored Strategy
Innovative Expertise: Single-Domain Antibody Discovery
Characterization of SdAbs
Advanced Delivery
Targeted-Tailored Strategy
Innovative Expertise: Single-Domain Antibody Discovery
Characterization of SdAbs
Advanced Delivery
Targeted-Tailored Strategy
Innovative Expertise: Single-Domain Antibody Discovery
Characterization of SdAbs
Advanced Delivery
Our Progress
Innovative Solutions for Therapeutic Delivery and Beyond
Allergic Asthma
Phase
Target Validation
Discovery
Lead Candidate Selection
Pre-clinical Studies
Phase I
Allergic Asthma
Phase
Target Validation
Discovery
Lead Candidate Selection
Pre-clinical Studies
Phase I
Colorectal Carcinoma
Phase
Target Validation
Discovery
Lead Candidate Selection
Pre-clinical Studies
Phase I
Colorectal Carcinoma
Phase
Target Validation
Discovery
Lead Candidate Selection
Pre-clinical Studies
Phase I
Psoriasis
Phase
Target Validation
Discovery
Lead Candidate Selection
Pre-clinical Studies
Phase I
Psoriasis
Phase
Target Validation
Discovery
Lead Candidate Selection
Pre-clinical Studies
Phase I
Atopic Dermatitis
Phase
Target Validation
Discovery
Lead Candidate Selection
Pre-clinical Studies
Phase I
Atopic Dermatitis
Phase
Target Validation
Discovery
Lead Candidate Selection
Pre-clinical Studies
Phase I
Allergic Asthma
Phase
Target Validation
Discovery
Lead Candidate Selection
Pre-clinical Studies
Phase I
Colorectal Carcinoma
Phase
Target Validation
Discovery
Lead Candidate Selection
Pre-clinical Studies
Phase I
Psoriasis
Phase
Target Validation
Discovery
Lead Candidate Selection
Pre-clinical Studies
Phase I
Atopic Dermatitis
Phase
Target Validation
Discovery
Lead Candidate Selection
Pre-clinical Studies
Phase I
Administration
Biological X Galenical
Platform Potencial
Topical
Topical biologics for autoimmune diseases like psoriasis offer targeted treatment with reduced systemic side effects. Nanobodies can specifically address inflammatory cytokines, improving drug efficacy and patient adherence. This approach provides faster relief and enhances quality of life for patients.
Inhalation
Inhaled biologics for asthma deliver targeted treatment directly to the airways, enhancing efficacy and reducing systemic side effects. Monoclonal antibodies can specifically block inflammatory molecules, improving symptom relief and patient adherence. This method provides faster action and better quality of life.
Injectables
Injectable biologics offer significant potential for chronic disease management by delivering therapeutic agents directly into the bloodstream. This targeted approach enhances symptom relief, slows disease progression, and improves patient function and quality of life.
Oral
Oral biologics for inflammatory bowel diseases provide targeted treatment directly to the gut, reducing inflammation and symptoms. This approach improves drug efficacy and patient adherence, offering a more convenient option that enhances quality of life.
DNA and RNA
based therapiesGene therapy for melanoma represents an innovative approach, using advanced techniques to modify patients' genetic material to target tumor cells or boost the immune response. This method offers highly specific treatment, reducing systemic side effects and improving efficacy, and provides new options for advanced or resistant cases.
Topical
Topical biologics for autoimmune diseases like psoriasis offer targeted treatment with reduced systemic side effects. Nanobodies can specifically address inflammatory cytokines, improving drug efficacy and patient adherence. This approach provides faster relief and enhances quality of life for patients.
Inhalation
Inhaled biologics for asthma deliver targeted treatment directly to the airways, enhancing efficacy and reducing systemic side effects. Monoclonal antibodies can specifically block inflammatory molecules, improving symptom relief and patient adherence. This method provides faster action and better quality of life.
Injectables
Injectable biologics offer significant potential for chronic disease management by delivering therapeutic agents directly into the bloodstream. This targeted approach enhances symptom relief, slows disease progression, and improves patient function and quality of life.
Oral
Oral biologics for inflammatory bowel diseases provide targeted treatment directly to the gut, reducing inflammation and symptoms. This approach improves drug efficacy and patient adherence, offering a more convenient option that enhances quality of life.
DNA and RNA
based therapiesGene therapy for melanoma represents an innovative approach, using advanced techniques to modify patients' genetic material to target tumor cells or boost the immune response. This method offers highly specific treatment, reducing systemic side effects and improving efficacy, and provides new options for advanced or resistant cases.
Administration
Biological X Galenical
Platform Potencial
Topical
Topical biologics for autoimmune diseases like psoriasis offer targeted treatment with reduced systemic side effects. Nanobodies can specifically address inflammatory cytokines, improving drug efficacy and patient adherence. This approach provides faster relief and enhances quality of life for patients.
Inhalation
Inhaled biologics for asthma deliver targeted treatment directly to the airways, enhancing efficacy and reducing systemic side effects. Monoclonal antibodies can specifically block inflammatory molecules, improving symptom relief and patient adherence. This method provides faster action and better quality of life.
Injectables
Injectable biologics offer significant potential for chronic disease management by delivering therapeutic agents directly into the bloodstream. This targeted approach enhances symptom relief, slows disease progression, and improves patient function and quality of life.
Oral
Oral biologics for inflammatory bowel diseases provide targeted treatment directly to the gut, reducing inflammation and symptoms. This approach improves drug efficacy and patient adherence, offering a more convenient option that enhances quality of life.
DNA and RNA
based therapiesGene therapy for melanoma represents an innovative approach, using advanced techniques to modify patients' genetic material to target tumor cells or boost the immune response. This method offers highly specific treatment, reducing systemic side effects and improving efficacy, and provides new options for advanced or resistant cases.
Team & Advisory
Our Team
Who support us
Latest Updates
Stay Informed and Updated
March 29, 2023
Local delivery of optimized nanobodies targeting the PD-1/PD-L1 axis with a self-amplifying RNA viral vector induces potent antitumor responses
Local delivery of optimized nanobodies targeting the PD-1/PD-L1 axis with a self-amplifying RNA viral vector induces potent antitumor responses
March 29, 2023
Local delivery of optimized nanobodies targeting the PD-1/PD-L1 axis with a self-amplifying RNA viral vector induces potent antitumor responses
Local delivery of optimized nanobodies targeting the PD-1/PD-L1 axis with a self-amplifying RNA viral vector induces potent antitumor responses
March 29, 2023
Local delivery of optimized nanobodies targeting the PD-1/PD-L1 axis with a self-amplifying RNA viral vector induces potent antitumor responses
Local delivery of optimized nanobodies targeting the PD-1/PD-L1 axis with a self-amplifying RNA viral vector induces potent antitumor responses
Contact
Partner with Us
Contact us to explore how we can collaborate to drive progress and achieve impactful results together.
Contact
Partner with Us
Contact us to explore how we can collaborate to drive progress and achieve impactful results together.
Contact
Partner with Us
Contact us to explore how we can collaborate to drive progress and achieve impactful results together.